AKINBORO O, DREZNER N, AMATYA A, et al. US Food and Drug Administration Approval Summary: Nivolumab Plus Platinum-Doublet Chemotherapy for the Neoadjuvant Treatment of Patients With Resectable Non–Small-Cell Lung Cancer[J]. Journal of Clinical Oncology, 2023, 41(17): 3249-3259.